Evaluation of Intraocular Pressure Following a Vitreoretinal Surgery Using Goldmann Applanation Tonometry, Icare and Accupen
Launched by CHU DE QUEBEC-UNIVERSITE LAVAL · Jul 25, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well two different devices, Icare and Accupen, measure eye pressure compared to the standard method called Goldmann applanation tonometry (GAT) after patients have undergone vitreo-retinal surgery. The main goal is to see if Icare and Accupen provide measurements that are just as accurate as GAT one day after the surgery. This is important because knowing the right eye pressure can help doctors ensure everything is healing properly.
To participate in this study, individuals must be at least 18 years old and have had vitreoretinal surgery. However, people with certain eye conditions, like corneal issues or a history of specific eye surgeries, will not be eligible to join. If someone decides to take part, they will have their eye pressure checked using all three devices the day after their surgery. This trial is currently recruiting participants of all genders, and it aims to gather important information that could improve how doctors measure eye pressure after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18
- • Received a vitreoretinal surgery
- Exclusion Criteria:
- • Corneal dystrophy
- • Corneal surgery (penetrating keratoplasty, DSAEK/DMEK less than 6 months, radial keratotomy)
- • Irregular corneal surface
- • Active corneal ulcer
- • Active epithelial deficit
- • Central corneal scarring
- • A history of scleral buckle
About Chu De Quebec Universite Laval
CHU de Québec-Université Laval is a leading academic health center in Canada, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, it leverages its extensive network of healthcare professionals, researchers, and state-of-the-art facilities to conduct innovative clinical studies across various therapeutic areas. With a strong emphasis on collaboration and ethical standards, CHU de Québec-Université Laval aims to translate scientific discoveries into effective treatments, enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Québec, Quebec, Canada
Québec, , Canada
Patients applied
Trial Officials
Mathieu Caissie, MD
Principal Investigator
CHU de Québec - Université Laval
Imad E Hachem, MD
Principal Investigator
CHU de Québec - Université Laval
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported